KR102628235B1 - 혈액 악성종양을 치료, 진단 및 예측하기 위한 방법 - Google Patents

혈액 악성종양을 치료, 진단 및 예측하기 위한 방법 Download PDF

Info

Publication number
KR102628235B1
KR102628235B1 KR1020167035701A KR20167035701A KR102628235B1 KR 102628235 B1 KR102628235 B1 KR 102628235B1 KR 1020167035701 A KR1020167035701 A KR 1020167035701A KR 20167035701 A KR20167035701 A KR 20167035701A KR 102628235 B1 KR102628235 B1 KR 102628235B1
Authority
KR
South Korea
Prior art keywords
htr
type
cells
delete delete
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167035701A
Other languages
English (en)
Korean (ko)
Other versions
KR20170021253A (ko
Inventor
루트 무뇨스 리수에뇨
Original Assignee
푼다시오 인스티뚜트 데 레세르카 꼰뜨라 라 레우세미아 요셉 까를레라스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 푼다시오 인스티뚜트 데 레세르카 꼰뜨라 라 레우세미아 요셉 까를레라스 filed Critical 푼다시오 인스티뚜트 데 레세르카 꼰뜨라 라 레우세미아 요셉 까를레라스
Publication of KR20170021253A publication Critical patent/KR20170021253A/ko
Application granted granted Critical
Publication of KR102628235B1 publication Critical patent/KR102628235B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G01N33/57426—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020167035701A 2014-06-27 2015-06-26 혈액 악성종양을 치료, 진단 및 예측하기 위한 방법 Active KR102628235B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382249.2A EP2959904A1 (en) 2014-06-27 2014-06-27 Methods for treating, diagnosing and prognosing a haematological malignancy
EP14382249.2 2014-06-27
PCT/EP2015/064571 WO2015197839A1 (en) 2014-06-27 2015-06-26 Methods for treating, diagnosing and prognosing a haematological malignancy

Publications (2)

Publication Number Publication Date
KR20170021253A KR20170021253A (ko) 2017-02-27
KR102628235B1 true KR102628235B1 (ko) 2024-01-22

Family

ID=51162662

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167035701A Active KR102628235B1 (ko) 2014-06-27 2015-06-26 혈액 악성종양을 치료, 진단 및 예측하기 위한 방법

Country Status (15)

Country Link
US (4) US10195207B2 (https=)
EP (2) EP2959904A1 (https=)
JP (2) JP2017526629A (https=)
KR (1) KR102628235B1 (https=)
CN (1) CN106471373B (https=)
AU (2) AU2015279105B2 (https=)
BR (1) BR112016029562B1 (https=)
CA (1) CA2953272C (https=)
DK (1) DK3160472T3 (https=)
ES (1) ES2796056T3 (https=)
IL (1) IL249579B (https=)
MX (1) MX362049B (https=)
RU (1) RU2727418C2 (https=)
WO (1) WO2015197839A1 (https=)
ZA (1) ZA201700080B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6843225B2 (ja) * 2016-07-28 2021-03-17 チャンスー ヤホン メディテック カンパニー リミテッド 癌の処置のためのドーパミンβ−ヒドロキシラーゼ（ＤＢＨ）阻害剤およびセロトニン受容体（５−ＨＴ）アンタゴニストの使用
EP3348266A1 (en) * 2017-01-16 2018-07-18 Leukos Biotech, S.L. Combination therapy for treating cancer
JP7002245B2 (ja) * 2017-08-10 2022-01-20 シスメックス株式会社 血液分析装置、血液分析方法およびプログラム
US11426408B2 (en) * 2017-11-01 2022-08-30 National University Of Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
HUE070062T2 (hu) 2018-01-18 2025-05-28 Leukos Biotech S L Apomorfin-palmitinsav kokristály szilárd részecske kristályos forma
US11034751B1 (en) 2018-01-30 2021-06-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating cancer using serotonin receptor inhibitors
CN111257558B (zh) * 2020-01-19 2021-08-24 江苏省人民医院（南京医科大学第一附属医院） 基于机器学习的慢性淋巴细胞白血病肿瘤细胞识别方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155669A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 2, 4, 8-triaza-spiro (4, 5) dec-2-enes
US3155670A (en) 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
NL300886A (https=) 1962-11-23
US3471515A (en) 1965-02-01 1969-10-07 Sandoz Ag (2-hydroxy-3-substituted aminopropoxy)indoles
US3466325A (en) 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
DE1668055B2 (de) 1967-03-10 1973-09-06 Farbwerke Hoechst AG, vormals Mei ster Lucius & Bruning, 6000 Frankfurt Basisch substituierte cyclopentylphenolaether, deren salze mit physiologisch vertraeglichen saeuren und verfahren zu deren herstellung
GB1308191A (en) 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
KR20040055311A (ko) * 2002-12-20 2004-06-26 주식회사 피앤아이 컨설팅 악성혈액종양 진단용 칩 및 이를 이용한 예후판단 시스템
ES2306983T3 (es) * 2003-02-17 2008-11-16 Bayer Healthcare Ag Diagnosticos y tratamientos para enfermedades hematologicas asociadas con el receptor 5-hidroxitriptamina-1f(5-ht1f).
WO2008098351A1 (en) * 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
WO2008146101A1 (en) * 2007-06-01 2008-12-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Ligands of hvem for treating hematologic malignancies and autoimmune diseases
CA2716424C (en) * 2008-03-04 2015-04-28 Pfizer Limited Methods of treating chronic pain
SG176571A1 (en) * 2009-05-19 2012-01-30 Vivia Biotech Sl Methods for providing personalized medicine tests ex vivo for hematological neoplasms
WO2015079439A1 (en) * 2013-11-26 2015-06-04 Technion Research And Development Foundation Limited Neuronal modulation
US20150197839A1 (en) * 2014-01-13 2015-07-16 Maria Celeste Rellamas Tria Forming conductive pattern using titania sol-gel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Papiez, Monika A., et al. "Evaluation of oxidative status and depression-like responses in Brown Norway rats with acute myeloid leukemia." Progress in Neuro-Psychopharmacology and Biological Psychiatry 33.4 (2009): 596-604.*

Also Published As

Publication number Publication date
JP6846551B2 (ja) 2021-03-24
US20170143735A1 (en) 2017-05-25
ES2796056T3 (es) 2020-11-25
US20210228593A1 (en) 2021-07-29
US10195207B2 (en) 2019-02-05
AU2020200010B2 (en) 2020-11-19
EP2959904A1 (en) 2015-12-30
BR112016029562B1 (pt) 2021-07-06
MX362049B (es) 2019-01-04
AU2020200010A1 (en) 2020-01-30
BR112016029562A2 (pt) 2017-08-22
EP3160472B1 (en) 2020-03-11
RU2016147748A3 (https=) 2019-02-13
US20220323456A1 (en) 2022-10-13
EP3160472A1 (en) 2017-05-03
IL249579B (en) 2019-03-31
CA2953272A1 (en) 2015-12-30
KR20170021253A (ko) 2017-02-27
ZA201700080B (en) 2019-04-24
US11337984B2 (en) 2022-05-24
CN106471373A (zh) 2017-03-01
RU2727418C2 (ru) 2020-07-21
IL249579A0 (en) 2017-02-28
CN106471373B (zh) 2019-08-23
AU2015279105A1 (en) 2016-12-15
US20190343843A1 (en) 2019-11-14
MX2016016994A (es) 2017-06-09
CA2953272C (en) 2022-10-04
WO2015197839A1 (en) 2015-12-30
AU2015279105B2 (en) 2019-10-03
JP2017526629A (ja) 2017-09-14
RU2016147748A (ru) 2018-08-03
JP2020097608A (ja) 2020-06-25
DK3160472T3 (da) 2020-06-02

Similar Documents

Publication Publication Date Title
JP6846551B2 (ja) 血液系悪性腫瘍を治療、診断および予後判定するための方法
CN102272599B (zh) 抗cxcr1组合物和方法
CN107406881B (zh) 用于指导癌症治疗的内容相关的诊断测试
KR20190140917A (ko) 암 치료용 의약 조성물
WO2015010094A1 (en) Differential bh3 mitochondrial profiling
Zarbock et al. The Duffy antigen receptor for chemokines in acute renal failure: A facilitator of renal chemokine presentation
WO2023092119A2 (en) Methods for predicting responsiveness to a cancer therapy
CN118369116A (zh) 包含肿瘤免疫的小分子调节物的组合物及其使用方法
US20250003986A1 (en) K17 as a biomarker for tumor response to immunotherapy
Ai et al. SDF-1 promotes metastasis of NSCLC by enhancing chemoattraction of megakaryocytes through the PI3K/Akt signaling pathway: Yiguo Ai et al.
US10865415B2 (en) Prevention, diagnosis and treatment of cancer overexpressing GPR160
WO2019025608A1 (en) METHODS OF TREATING LEUKEMIA WITH AN INHIBITOR OF GLASS NEURONE ANTIGEN 2
JP2025146792A (ja) 白血病の髄外浸潤マーカー
WO2019055930A1 (en) METHODS OF IDENTIFYING MYELOMA TUMOR INITIATOR CELLS AND TARGETED THERAPY
WO2024227553A1 (en) Biomarkers for use in cancer treatment and predicting responsiveness to a cancer therapy
TW202523288A (zh) 利用拉索昔芬（lasofoxifene）之實體癌症治療
BLASTS Myeloproliferative Disorders-Biology
Thomas Genetic and Chemical Modulators of JAK/STAT Signalling in Cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000